Catalent, Inc. (NYSE:CTLT) Holdings Boosted by Nomura Holdings Inc.

Nomura Holdings Inc. boosted its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 149.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,487,342 shares of the company's stock after buying an additional 6,881,914 shares during the quarter. Catalent makes up 1.4% of Nomura Holdings Inc.'s portfolio, making the stock its 3rd largest position. Nomura Holdings Inc. owned 6.36% of Catalent worth $516,126,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of CTLT. KB Financial Partners LLC bought a new position in shares of Catalent during the 1st quarter worth approximately $30,000. Covestor Ltd raised its stake in shares of Catalent by 84.9% during the 1st quarter. Covestor Ltd now owns 562 shares of the company's stock worth $62,000 after acquiring an additional 258 shares in the last quarter. Gladius Capital Management LP purchased a new stake in Catalent during the 3rd quarter worth approximately $28,000. Exchange Traded Concepts LLC purchased a new stake in Catalent during the 3rd quarter worth approximately $31,000. Finally, GAMMA Investing LLC purchased a new stake in Catalent during the 4th quarter worth approximately $33,000.

Catalent Price Performance

NYSE:CTLT traded down $0.21 during trading hours on Friday, reaching $56.75. 1,099,014 shares of the company were exchanged, compared to its average volume of 1,880,345. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The stock's 50-day moving average is $56.63 and its 200-day moving average is $47.53. The firm has a market cap of $10.26 billion, a PE ratio of -8.35, a price-to-earnings-growth ratio of 6.14 and a beta of 1.20. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $67.54.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business's revenue was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.62 earnings per share. On average, sell-side analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on CTLT shares. Stephens reaffirmed an "equal weight" rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday. Barclays upped their price objective on shares of Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a report on Thursday, January 25th. UBS Group reaffirmed a "neutral" rating and issued a $63.50 price objective (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Finally, StockNews.com started coverage on shares of Catalent in a report on Wednesday. They issued a "sell" rating on the stock. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.